Virginia Commonwealth University Massey Cancer Center

What Virginia Commonwealth University Massey Cancer Center does

VCU Massey Comprehensive Cancer Center is an NCI-designated Comprehensive Cancer Center and component of Virginia Commonwealth University, a public state research university. Established in 1974 and NCI-funded continuously since 1975, Massey is one of only 58 NCI-designated Comprehensive Cancer Centers in the United States and one of two in Virginia. The center delivers multidisciplinary cancer care across 50+ cancer types — including chemotherapy, radiation oncology, surgical oncology, cellular immunotherapies, bone marrow transplant, precision cancer treatment, and integrative medicine — to adult and pediatric patients drawn primarily from a 66-locality catchment area across eastern, central, and southern Virginia, supplemented by telehealth and NCORP-affiliated community sites.

The center runs an active research enterprise spanning basic, translational, clinical, and population science across three core programs (Cancer Biology, Developmental Therapeutics, and Cancer Prevention & Control), supported by shared resource cores including Flow Cytometry, advanced Microscopy, Proteomics, Bioinformatics, Biostatistics, Tissue and Data Acquisition, Cancer Mouse Models, and Lipidomics/Metabolomics. Notable research initiatives include an AI-driven patient-derived tumor organoid platform co-developed with UCLA and the University of Colorado, RAS(ON) inhibitor research (daraxonrasib/KRAS G12D combinations) in pancreatic cancer, tumor-infiltrating lymphocyte therapy, and GLP-1 receptor agonist cancer outcome studies. The center also trains the next generation through an NCI-funded T32 fellowship in cancer biology.

Massey's revenue model combines clinical care services billed to patients and insurers, federally funded research (NCI Cancer Center Support Grant, NIH grants), pharma- and cooperative-group-sponsored clinical trial reimbursements, and philanthropic contributions via the VCU Foundation. It has no independent commercial funding, no public ticker, and operates as a non-profit government state entity. Distribution is through direct patient intake at the VCU Health Medical Campus in Richmond, a referring physician network across Virginia, clinical trial enrollment, NCORP affiliates, and telehealth, supported by an integrated marketing and community engagement operation.

Name

Virginia Commonwealth University Massey Cancer Center

Legal name

Virginia Commonwealth University Massey Comprehensive Cancer Center

Website

https://masseycancercenter.org

Company type

Public

Founded year

1974

Operating status

Operating

Headcount range

251–500 employees

Short description

VCU Massey Comprehensive Cancer Center is an NCI-designated Comprehensive Cancer Center (one of 58 in the U.S.) providing multidisciplinary cancer care, 200+ clinical trials, and translational research across 50+ cancer types to adult and pediatric patients throughout Virginia.

Ownership category

akta.pro rank

Product category

Cancer Care and Research Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310)

SIC

Services-General Medical & Surgical Hospitals, Nec (8062), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Medical Oncology (HLAKAFAB), Radiation Oncology (HLAKAFAC), Oncology Telemedicine Platforms (HLALAGAH)

Keywords

• Cancer treatment services
• Clinical trial research
• Radiation oncology
• Cellular immunotherapy
• Precision oncology

Headquarters

HQ city

Richmond

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Care Services: Massey generates revenue through providing cancer treatment and care services to patients, including chemotherapy, radiation oncology, surgery, cellular immunotherapies, and other cancer treatments. Services are billed to patients' insurance or covered under clinical trial funding.
2. Clinical Trial Participation: Massey participates in clinical trials funded by government agencies (NCI, NIH), pharmaceutical companies, and cooperative research groups. Trial costs are covered by trial funding or billed to insurance for standard-of-care components.
3. Research Funding and Grants: Massey receives significant research funding through NCI Cancer Center Support Grant (CCSG), federal grants (NIH, NCI), and institutional research grants. The center has been continuously funded by an NCI CCSG since 1975.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels9 records

Core offering

VCU Massey Comprehensive Cancer Center provides multidisciplinary cancer diagnosis, treatment, and survivorship care across 50+ cancer types for adult and pediatric patients through chemotherapy, radiation oncology, surgical oncology, cellular immunotherapies (including bone marrow transplant and TIL therapy), and precision cancer treatment. The center also conducts basic, clinical, translational, and population science cancer research, offering access to over 200 clinical trials, while training the next generation of oncology scientists and clinicians.

Product overview

VCU Massey Comprehensive Cancer Center is an NCI-designated Comprehensive Cancer Center offering a comprehensive portfolio of cancer care services organized as a single integrated healthcare delivery system. The center provides multidisciplinary treatment across 50+ cancer types through specialized services including chemotherapy, radiation oncology, surgery (including robotic), cellular immunotherapies, bone marrow transplant, precision cancer treatment, and integrative medicine. The institution supports over 200 clinical trials for adult and pediatric patients, a survivorship program for post-treatment care, and education/training programs including the NCI-funded T32 Integrative Training in Cancer Biology fellowship. Treatment services are delivered through multidisciplinary teams integrating medical and radiation oncologists, surgeons, pathologists, genetic counselors, and support staff.

Differentiator

Problem solved

Functional benefit

Products and services

• Chemotherapy

Quantifiable outcome

• Median overall survival more than 13 months with daraxonrasib vs. less than 7 months with chemotherapy in advanced pancreatic cancer (RASolute 302 trial)
• +3 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• American Society of Clinical Oncology (ASCO)coreStrategic or Co-development Partner · 29 May 2026Massey had significant presence at the 2026 ASCO Annual Meeting with over 30 poster presentations. The VCU Massey booth served as a networking hub showcasing the center's research on an international stage.
• UCLA Health Jonsson Comprehensive Cancer CentercoreStrategic or Co-development PartnerCollaborative partnership in AI-driven platform development combining 3D bioprinting, label-free quantitative phase imaging, and machine learning to create patient-derived tumor organoids for drug discovery and personalized cancer therapy planning. This multi-institutional effort also includes funding from U.S. government agencies.
• University of Colorado School of MedicinecoreStrategic or Co-development PartnerCollaborative partner in the development of AI-driven platform for patient-derived tumor organoids, combining expertise in 3D bioprinting, quantitative imaging, and machine learning for precision oncology research.
• LeonaBiominorStrategic or Co-development PartnerLeonaBio is a clinical-stage biopharmaceutical company developing lasofoxifene. Independent researchers at Massey presented nonclinical data on lasofoxifene at AACR26, showing bone protection effects in ER+ breast cancer models. Findings align with LeonaBio's ongoing ELAINE-3 Phase 3 trial.
• ALLIANCE for Clinical Trials in OncologycoreStrategic or Co-development PartnerCooperative research group through which Massey offers clinical trials. Working in unison with member institutions following same protocols for each trial to expand patient enrollment and accelerate research.
• ECOG-ACRIN Cancer Research GroupcoreStrategic or Co-development PartnerCooperative research group providing access to clinical trials. Cooperative groups help expand patient numbers, collect more data, and accelerate research through multi-center collaboration.
• NRG OncologycoreStrategic or Co-development PartnerCooperative research group offering clinical trials. Massey participates as part of collaborative efforts among multiple cancer centers organized into national groups.
• Children's Oncology GroupcoreStrategic or Co-development PartnerCooperative group providing access to pediatric clinical trials. Massey offers both adult and pediatric patients access to cancer treatment trials through these collaborative networks.
• NCI Experimental Therapeutics Clinical Trials Network (ETCTN)coreStrategic or Co-development PartnerNCI network providing access to experimental therapeutics clinical trials. Massey participates in or has access to trials from this national consortium.
• SWOG Cancer Research NetworkcoreStrategic or Co-development PartnerCooperative research network providing clinical trial access. Massey participates in this group offering same studies and following same protocols for consistent data collection.
• Wake Forest NCORP Research BasecoreStrategic or Co-development PartnerNCORP research base providing community-based clinical trial access. Massey and its NCORP affiliates expand clinical trial availability across Virginia.
• Blood and Marrow Transplant Clinical Trials NetworkcoreStrategic or Co-development PartnerSpecialized cooperative network for blood and marrow transplant clinical trials. Massey participates through this network for cellular immunotherapy and transplant programs.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Duke Cancer Institute: NCI-designated Comprehensive Cancer Center at Duke University with a comparable academic research + clinical care model, competing with Massey for Mid-Atlantic patients, clinical trial enrollment, and oncology talent.
• Vanderbilt-Ingram Cancer Center: NCI Comprehensive Cancer Center at Vanderbilt with parallel research programs in cancer biology, developmental therapeutics, and prevention; competes with Massey for cooperative-group leadership and pharma-sponsored early-phase trials.
• Memorial Sloan Kettering Cancer Center: The largest and most research-intensive NCI Comprehensive Cancer Center in the U.S., competing for high-impact trial enrollment, NEJM-caliber publications, and pancreatic and colorectal cancer research leadership that Massey also targets.
• Winship Cancer Institute of Emory University: NCI-designated Comprehensive Cancer Center at Emory with a similar academic health system structure, comparable clinical trial portfolio, and competing for Southeastern U.S. catchment-area patients and translational research funding.
• Johns Hopkins Sidney Kimmel Comprehensive Cancer Center: One of the original NCI-designated Comprehensive Cancer Centers, operating a similar integrated research-and-care model at far larger scale; competes with Massey for high-acuity referrals, trial sponsors, and faculty recruits in the Mid-Atlantic region.
• Fred Hutchinson Cancer Center: NCI-designated Comprehensive Cancer Center with world-leading programs in cellular immunotherapy (including TIL therapy), bone marrow transplantation, and population science; a direct peer for Massey's Cellular Immunotherapies and Transplant Program and translational research.
• UNC Lineberger Comprehensive Cancer Center: NCI Comprehensive Cancer Center at the University of North Carolina with similar structure to Massey: academic medical center, broad clinical trial portfolio, and cooperative-group participation competing for Southeastern U.S. oncology patients and research talent.

Others

• MD Anderson Cancer Center:

Direct peers

• University of Virginia Cancer Center: The other NCI-designated Comprehensive Cancer Center in Virginia, operating as a similarly structured academic cancer center within UVA Health with parallel research, clinical trial, and catchment-area missions that directly overlap with Massey in the same state.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/vcumassey
• YouTubeyoutube.com/user/TeamMassey
• Facebookfacebook.com/VCUMasseyCancerCenter
• LinkedInlinkedin.com/company/vcu-massey-cancer-center
• Instagraminstagram.com/vcumassey

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Virginia Commonwealth University Massey Cancer Center